Having trouble accessing articles? Reset your cache.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/15 cls
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Piper Jaffray Edward Tenthoff Downgrade Neutral (from overweight) -56% $1.32
Tenthoff also lowered his target to $1.35 from $3.50 after FDA issued a complete response letter for an NDA for Adusuve Staccato loxapine (AZ-004) to treat agitation in patients with schizophrenia or bipolar disorder. According to Alexza, the agency is concerned with data from three Phase

Read the full 875 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE